$BNGO
Bionano Genomics, Inc. Stock $bngo

$bngo Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000141169022000013 Filed on May 05, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$5.696M	$3.168M
YoY Change	79.8%	178.87%
Cost Of Revenue	$4.835M	$2.125M
YoY Change	127.53%	148.25%
Gross Profit	$861.0K	$1.043M
YoY Change	-17.45%	272.5%
Gross Profit Margin	15.12%	32.92%
Selling, General & Admin	$20.28M	$9.528M
YoY Change	112.81%	29.32%
% of Gross Profit	2355.05%	913.52%
Research & Development	$10.53M	$2.678M
YoY Change	293.09%	0.15%
% of Gross Profit	1222.65%	256.76%
Depreciation & Amortization	$2.210M	$448.0K
YoY Change	393.3%	51.35%
% of Gross Profit	256.68%	42.95%
Operating Expenses	$30.80M	$12.21M
YoY Change	152.37%	21.55%
Operating Profit	-$29.94M	-$11.16M
YoY Change	168.23%	14.35%
Interest Expense	$77.00K	$600.0K
YoY Change	-87.17%	-21.16%
% of Operating Profit
Other Income/Expense, Net	$0.00	$1.222M
YoY Change	-100.0%	-264.47%
Pretax Income	-$29.94M	-$9.941M
YoY Change	201.21%	-5.37%
Income Tax	$9.000K	$6.000K
% Of Pretax Income
Net Earnings	-$29.95M	-$9.947M
YoY Change	201.12%	-5.36%
Net Earnings / Revenue	-525.84%	-313.98%
Basic Earnings Per Share	-$0.11	-$0.04
Diluted Earnings Per Share	-$0.11	-$0.04
COMMON SHARES
Basic Shares Outstanding	284.6M shares	263.9M shares
Diluted Shares Outstanding	284.6M shares	263.9M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$216.4M	$362.1M
YoY Change	-40.24%	4370.37%
Cash & Equivalents	$24.00M	$362.1M
Short-Term Investments	$192.4M
Other Short-Term Assets	$4.110M	$3.200M
YoY Change	28.44%	190.91%
Inventory	$16.27M	$3.036M
Prepaid Expenses
Receivables	$5.514M	$1.992M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$242.4M	$370.3M
YoY Change	-34.54%	2080.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.66M	$5.806M
YoY Change	118.07%	173.87%
Goodwill	$56.25M	$7.173M
YoY Change	684.25%
Intangibles	$25.42M	$1.396M
YoY Change	1721.2%
Long-Term Investments
YoY Change
Other Assets	$798.0K	$235.0K
YoY Change	239.57%
Total Long-Term Assets	$105.9M	$14.61M
YoY Change	624.51%	589.15%
TOTAL ASSETS
Total Short-Term Assets	$242.4M	$370.3M
Total Long-Term Assets	$105.9M	$14.61M
Total Assets	$348.2M	$384.9M
YoY Change	-9.52%	1914.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.590M	$2.209M
YoY Change	198.33%	-30.45%
Accrued Expenses	$8.936M	$4.659M
YoY Change	91.8%	70.97%
Deferred Revenue	$1.107M	$301.0K
YoY Change	267.77%	-5.35%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$296.0K
YoY Change
Total Short-Term Liabilities	$18.66M	$7.169M
YoY Change	160.27%	-69.08%
LONG-TERM LIABILITIES
Long-Term Debt	$3.638M	$14.87M
YoY Change	-75.53%
Other Long-Term Liabilities	$14.73M	$100.0K
YoY Change	14629.0%
Total Long-Term Liabilities	$18.37M	$14.87M
YoY Change	23.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.66M	$7.169M
Total Long-Term Liabilities	$18.37M	$14.87M
Total Liabilities	$37.03M	$22.14M
YoY Change	67.21%	-5.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$246.1M	-$153.6M
YoY Change	60.17%	35.85%
Common Stock	$558.9M	$516.3M
YoY Change	8.24%	374.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$311.2M	$362.7M
YoY Change
Total Liabilities & Shareholders Equity	$348.2M	$384.9M
YoY Change	-9.52%	1914.77%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$29.95M	-$9.947M
YoY Change	201.12%	-5.36%
Depreciation, Depletion And Amortization	$2.210M	$448.0K
YoY Change	393.3%	51.35%
Cash From Operating Activities	-$32.49M	-$13.90M
YoY Change	133.7%	73.11%
INVESTING ACTIVITIES
Capital Expenditures	-$982.0K	$24.00K
YoY Change	-4191.67%
Acquisitions	-$694.0K	$0.00
YoY Change
Other Investing Activities	$32.95M
YoY Change
Cash From Investing Activities	$31.96M	-$24.00K
YoY Change	-133283.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$328.6M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$7.000K	$337.5M
YoY Change	-100.0%	-29838.85%
NET CHANGE
Cash From Operating Activities	-$32.49M	-$13.90M
Cash From Investing Activities	$31.96M	-$24.00K
Cash From Financing Activities	$7.000K	$337.5M
Net Change In Cash	-$523.0K	$323.6M
YoY Change	-100.16%	-3630.14%
FREE CASH FLOW
Cash From Operating Activities	-$32.49M	-$13.90M
Capital Expenditures	-$982.0K	$24.00K
Free Cash Flow	-$31.51M	-$13.93M
YoY Change	126.25%	73.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001411690
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1756290
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Bionano Genomics, Inc.
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P9M
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-38613
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9540 Towne Centre Drive, Suite 100
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2022Q1	dei	City Area Code CityAreaCode	858
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	888-7600
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	226041000	USD
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	289697045	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24048000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24571000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	192420000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	463000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	690000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5514000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4934000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	16268000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6817000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	12387000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4110000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4481000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	242360000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	272414000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12661000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10318000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6691000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3897000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3926000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	25424000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26842000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	56254000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	56160000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	798000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1107000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	749000	USD
CY2022Q1	us-gaap	Assets Assets	348211000	USD
CY2021Q4	us-gaap	Assets Assets	377100000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6590000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9696000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8936000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9694000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	684000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1730000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1467000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	296000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	299000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	18659000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21840000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5451000	USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5288000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3638000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3642000	USD
CY2022Q1	bngo	Contingent Consideration Fair Value Of Contingent Liability ContingentConsiderationFairValueOfContingentLiability	9145000	USD
CY2021Q4	bngo	Contingent Consideration Fair Value Of Contingent Liability ContingentConsiderationFairValueOfContingentLiability	9066000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	133000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	146000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	37026000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	39982000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	289688000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	289688000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	289602000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	289602000	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	558864000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	553747000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-246071000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216119000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1637000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-539000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	311185000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	337118000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	348211000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	377100000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5696000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3168000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4835000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2125000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10527000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2678000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20277000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9528000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	30804000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	12206000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-29943000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11163000	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	110000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	65000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	77000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	603000	USD
CY2022Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	0	USD
CY2021Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1775000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	0	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1222000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29943000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9941000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-29952000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9947000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	284613000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	284613000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	263939000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	263939000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-29952000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9947000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1098000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31050000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9947000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	35082000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	333000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	371000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	327486000	USD
CY2021Q1	bngo	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	9393000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9947000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	362718000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	337118000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5102000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-29952000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1098000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	311185000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-29952000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9947000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2210000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	448000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	29000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	0	USD
CY2022Q1	us-gaap	Accretion Expense AccretionExpense	299000	USD
CY2021Q1	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2022Q1	bngo	Noncash Interest Expense NoncashInterestExpense	299000	USD
CY2021Q1	bngo	Noncash Interest Expense NoncashInterestExpense	0	USD
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	315000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5102000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	371000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	79000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2022Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	0	USD
CY2021Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1775000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	640000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-783000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5938000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	961000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	371000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1049000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3168000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1045000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-443000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1044000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32494000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13904000	USD
CY2022Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-694000	USD
CY2021Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2022Q1	bngo	Payments For Property And Equipment PaymentsForPropertyAndEquipment	150000	USD
CY2021Q1	bngo	Payments For Property And Equipment PaymentsForPropertyAndEquipment	24000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	14954000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	47179000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2022Q1	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	832000	USD
CY2021Q1	us-gaap	Payments For Construction In Process PaymentsForConstructionInProcess	0	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	27000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	31964000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-24000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	8000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	328635000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9726000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	337536000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-523000	USD
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	825000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	323608000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24571000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38449000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24048000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362057000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	70000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	287000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	217000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	206000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	300000	USD
CY2022Q1	bngo	Transfer Of Instruments And Servers To Property And Equipment From Inventory TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory	2056000	USD
CY2021Q1	bngo	Transfer Of Instruments And Servers To Property And Equipment From Inventory TransferOfInstrumentsAndServersToPropertyAndEquipmentFromInventory	1240000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	513000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2013000	USD
CY2022Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	0	USD
CY2021Q1	bngo	Gain Loss On Forgiveness Of Paycheck Protection Program Loan GainLossOnForgivenessOfPaycheckProtectionProgramLoan	1775000	USD
CY2022Q1	bngo	Offering Costs Incurred Not Yet Paid OfferingCostsIncurredNotYetPaid	0	USD
CY2021Q1	bngo	Offering Costs Incurred Not Yet Paid OfferingCostsIncurredNotYetPaid	324000	USD
CY2022Q1	bngo	Warrant Exercise Non Cash WarrantExerciseNonCash	0	USD
CY2021Q1	bngo	Warrant Exercise Non Cash WarrantExerciseNonCash	129000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5696000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24000000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	192400000	USD
CY2022Q1	bngo	Working Capital WorkingCapital	223700000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30730000	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9537000	shares
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.758
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.033
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3168000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5696000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3168000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1200000	USD
CY2022Q1	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.209
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	200000	USD
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5977000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	5624000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	463000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	690000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5514000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4934000	USD
CY2022Q1	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	1139000	USD
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	745000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	15129000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11642000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	16268000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	12387000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28380000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2956000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25424000	USD
CY2020Q3	bngo	Sale Of Stock Authorized Amount To Be Issued SaleOfStockAuthorizedAmountToBeIssued	125000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	28380000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1538000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	26842000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3946000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4529000	USD
CY2022Q1	bngo	Accrued Inventory Current AccruedInventoryCurrent	1238000	USD
CY2021Q4	bngo	Accrued Inventory Current AccruedInventoryCurrent	1073000	USD
CY2022Q1	us-gaap	Deposit Liability Current DepositLiabilityCurrent	979000	USD
CY2021Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	826000	USD
CY2022Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	685000	USD
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	677000	USD
CY2022Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	389000	USD
CY2021Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1011000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	218000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	288000	USD
CY2022Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	175000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	38000000	USD
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	175000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1306000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1115000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8936000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9694000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	600000	USD
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	33400000	shares
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	38300000	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.05
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.00
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	101500000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	229600000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	27000000	shares
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2300000	shares
CY2021Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.15
CY2021Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	13900000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	600000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4356000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.96
CY2021	bngo	Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights	P1Y9M3D
CY2021Q4	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights	785000	USD
CY2022Q1	bngo	Class Of Warrant Or Right Number Of Securities Granted In Period ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod	0	shares
CY2022Q1	bngo	Class Of Warrant Or Right Number Of Securities Exercised In Period ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod	0	shares
CY2022Q1	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod	0
CY2022Q1	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights	0	USD
CY2022Q1	bngo	Class Of Warrant Or Right Number Of Securities Canceled In Period ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod	0	shares
CY2022Q1	bngo	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Cancelled In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsCancelledInPeriod	0
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4356000	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.96
CY2022Q1	bngo	Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights	P1Y9M3D
CY2022Q1	bngo	Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights	785000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12765000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7891000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9691000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.19
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.79
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	32000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	904000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.73
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21531000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.69
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M9D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10131000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	4018000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.66
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y10M17D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	3972000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.39
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5102000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	371000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.007
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.701
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.793
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2022Q1	bngo	Lessee Estimated Incremental Borrowing Rate LesseeEstimatedIncrementalBorrowingRate	0.071
CY2021	bngo	Lessee Estimated Incremental Borrowing Rate LesseeEstimatedIncrementalBorrowingRate	0.071
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6817000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6691000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1730000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1467000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5451000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5288000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7181000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6755000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2149000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3897000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	3926000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	296000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	299000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3638000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3642000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	3934000	USD
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	3941000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1538000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	236000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	322000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2219000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	330000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2305000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	338000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	232000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	347000	USD
CY2022Q1	bngo	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	0	USD
CY2022Q1	bngo	Finance Lease Liability To Be Paid After Year Four FinanceLeaseLiabilityToBePaidAfterYearFour	5949000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8443000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	7522000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1262000	USD
CY2022Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3588000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	7181000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	3934000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	51	tranche
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	57	tranche
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	USD

Files In Submission

Name	View Source	Status
0001411690-22-000013-index-headers.html	Edgar Link	pending
0001411690-22-000013-index.html	Edgar Link	pending
0001411690-22-000013.txt	Edgar Link	pending
0001411690-22-000013-xbrl.zip	Edgar Link	pending
bngo-20220331.htm	Edgar Link	pending
bngo-20220331.xsd	Edgar Link	pending
bngo-20220331xexx311.htm	Edgar Link	pending
bngo-20220331xexx312.htm	Edgar Link	pending
bngo-20220331xexx321.htm	Edgar Link	pending
bngo-20220331_cal.xml	Edgar Link	unprocessable
bngo-20220331_def.xml	Edgar Link	unprocessable
bngo-20220331_htm.xml	Edgar Link	completed
bngo-20220331_lab.xml	Edgar Link	unprocessable
bngo-20220331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BNGO
Bionano Genomics, Inc. Stock $bngo

2022 Q1 Form 10-Q Financial Statement

#000141169022000013 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNGO Bionano Genomics, Inc. Stock $bngo

2022 Q1 Form 10-Q Financial Statement

#000141169022000013 Filed on May 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BNGO
Bionano Genomics, Inc. Stock $bngo